.
OBJECTIVE:Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a serious pulmonary manifestation for which multidisciplinary ILD teams balance immunomodulation with antifibrotic therapy. The 2023 ACR/CHEST guideline recommends immunosuppressive therapy as first-line treatment for autoimmune ILD, but real-world agent-level documentation alongside antifibrotic therapy is poorly characterized. We characterized immunosuppressive medication documentation among seropositive RA-ILD patients stratified by antifibrotic documentation status. METHODS:Using a federated U.S. EHR network (TriNetX, academic medical centers), we identified three cohorts of seropositive adults: RA without ILD (N = 31,932), coded RA-ILD without antifibrotic documentation (N = 1885), and coded RA-ILD with repeated antifibrotic documentation (N = 115). Immunosuppressive medications documented within 90 days of each patient's analytic index date were compared descriptively. RESULTS:Methotrexate was documented in 52% of RA without ILD versus 12% of coded RA-ILD patients with repeated antifibrotic documentation. Azathioprine, mycophenolate, and rituximab were more frequently documented in coded RA-ILD. Among 98 coded RA-ILD patients with in-window antifibrotic documentation, 80.6% had at least one non-antifibrotic agent co-documented; 48 distinct medication sets were observed, with the most common set in 14.3% of patients. CONCLUSIONS:Medication documentation among coded RA-ILD patients with repeated antifibrotic documentation was more heterogeneous than in RA without ILD, with no dominant medication set. Methotrexate documentation was uncommon, whereas azathioprine, mycophenolate, and rituximab were more frequently documented. These descriptive findings provide agent-level reference data for interdisciplinary management of RA-ILD and identify hypotheses for future comparative-effectiveness research; they do not establish treatment indication or comparative effectiveness.
Abstract Purpose: The nonrandomized phase II trial Functional Lung Avoidance and Response-adaptive Escalation Radiation Therapy (FLARE-RT) tested personalized risk-adaptive radiotherapy for unresectable non–small cell lung cancer (NSCLC) using 2[18F]fluoro-2-deoxy-D-glucose (FDG)-PET/CT and single-photon emission computed tomography/CT. We report radiation dosimetry, mature outcomes, adverse events, failure patterns, and risk stratification models. Patients and Methods: Forty-nine patients with American Joint Committee on Cancer version 7 stage IIB–IIIB NSCLC enrolled in FLARE-RT (NCT02773238) from 2016 to 2021 and initiated chemoradiation. Patients with week 3 FDG-PET response received 60 Gy in 30 fractions. Patients with nonresponse received concomitant boosts from weeks 4 to 6 to residual metabolic disease of 74 to 90 Gy total guided by FDG uptake. Overall survival (OS; primary endpoint) and progression-free survival (PFS) were estimated via Kaplan–Meier. Locoregional progression (LRP) and distant metastasis (DM) cumulative incidence were estimated via Aalen–Johansen, with death and alternative progression patterns as competing risks. Predictors of treatment failure modes were identified through Fine–Gray regression. Results: The median patient age was 63.2 years, with predominantly adenocarcinoma histology (n = 30, 61.2%), N2 nodal disease (n = 31, 63.3%), smoking history (n = 41, 83.6%), and carboplatin–paclitaxel chemotherapy regimen (n = 31, 63.3%). Target volumes and normal tissue dosimetry were similar between PET responders (n = 33, 67.3%) and PET nonresponders (n = 16, 32.7%); PET-guided radiation boosts in select nonresponders did not increase the risk of adverse events except for grade 2 esophagitis. At 52.3 months median follow-up, 1- and 2-year OS was 81.6% [95% confidence interval (CI), 71.5%–93.2%] and 54.2% (95% CI, 41.8%–70.4%), respectively; median OS was 29.1 months (95% CI, 17.3–NA). One- and two-year PFS was 53.1% (95% CI, 40.9%–69%) and 40.5% (95% CI, 28.8%–57.0%), respectively; median PFS was 12.3 months (95% CI, 9.2–not reached). DM occurred in 18 of 31 cases and was the primary mode of failure. Cumulative incidence for 1- and 2-year LRP was 12.2% (95% CI, 4.9%–23.2%) and 18.5% (95% CI, 9.0%–30.6%), respectively; 1- and 2-year DM was 34.7% (95% CI, 21.7%–48.1%) and 43.1% (95% CI, 28.9%–56.5%), respectively. Higher pre-RT FDG-PET total lesion glycolysis (TLG) correlated with increased LRP [hazard ratio (HR) = 1.87 (95% CI, 1.41–2.49), P < 0.001], whereas higher mid-RT TLG correlated with DM [HR = 1.52 (95% CI, 1.05–2.21), P = 0.03]. Of 49 patients, 25 received durvalumab and exhibited lower 1-year DM (20% vs. 54.2%, P = 0.04) with no difference in 1-year LRP (20% vs. 4.2%, P = 0.27). Of 49 patients, 26 were treated with proton radiotherapy, yielding outcomes and failure patterns that were not different compared to those treated with photon therapy. Conclusions: Biological image-guided FLARE-RT achieved durable locoregional control with OS similar to RTOG 0617 (60 Gy arm)/RTOG 1106 (adaptive arm) and comparable with PACIFIC (durvalumab arm). Risk-adaptive radiation boosts in select patients were well tolerated with potential for improved disease control. Elevated TLG on baseline FDG-PET and residually on mid-treatment FDG-PET was associated with a greater risk of LRP and DM, respectively, which may refine selective radiotherapy and systemic therapy intensification. Validation of these findings is warranted in next-generation trials of imaging biomarker-guided and risk-adaptive therapy for unresectable NSCLC.
Minimizing patient radiation exposure when performing procedures under fluoroscopy is important for ensuring patient safety. Our primary objective in this quality improvement study was to assess trends in fluoroscopy time during image-guided lumbar punctures. In addition, we assessed the demographic and clinical factors that influenced fluoroscopy time during these procedures. Data on patient body mass index (BMI), patient age, and sedation method were obtained. In addition, information on the performing healthcare provider and date of procedure were obtained in order to derive the number of lumbar punctures previously performed by individual providers at the time of the procedure. Data were analyzed using ANOVA and a p<.05 was considered significant. A total of 370 fluoroscopy-guided lumbar punctures performed by resident physicians, attending physicians, and physician assistants were reviewed. A statistically significant difference in mean fluoroscopy time was identified in patients of differing ages with older age being associated with higher fluoroscopy times (p<0.01). No significant difference existed regarding patient BMI (p=0.16) or method of sedation (p=0.84) when compared to mean fluoroscopy time. A statistically significant decrease in fluoroscopy time was observed as more lumbar punctures were performed by clinicians (p=0.02). Significant increases in mean fluoroscopy times were observed in older patients, which may be secondary to degenerative changes of the spine making access to the thecal sac more difficult. No significant difference in mean fluoroscopy time was identified in regards to patient BMI or method of sedation. Using a formula derived from our data describing decreases in fluoroscopy time based on the number of procedures performed, it may be possible to predict how many lumbar punctures need to be performed by new trainees in order to reach certain levels of proficiency.
Platelet-rich plasma (PRP) therapy has emerged as a potential treatment option for osteoarthritis (OA) due to its ability to promote tissue healing and anti-inflammatory effects. More evidences are needed to establish the optimal therapy protocol. We present here a retrospective analysis of 252 patients treated with PRP for big joints OA between 2020 and 2022. We aimed to evaluate the benefits of PRP combined with rehabilitation on pain and function as well as the potential prognosis factors. We observed clinically significant improvements in pain (VAS improvement 49% at 6 months, 45% at 12 months) and function (Single Assessment Numeric Evaluation i.e. SANE score improvement 44% at 6 months, 39% at 12 months). Multiple PRP shoots and high sports activity, especially competition level, were found as favorable prognosis factors. The authors would suggest offering systematically PRP therapy for competition sports practitioners. Moreover, authors suggest that multiple PRP shoots, spaced from 3 to 4 weeks, could be a viable treatment option for OA.
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lungs but can involve other organs, termed extrapulmonary tuberculosis. Tuberculous pericarditis (TBP) is a rare form, representing approximately 1% of tuberculosis-related autopsies and 4% of acute pericarditis cases in developed countries. A 29-year-old healthy Indian man presented with fever, night sweats, and weight loss. Imaging revealed a large pericardial effusion with tamponade physiology. He underwent pericardiocentesis and a surgical pericardial window, with biopsy confirming M. tuberculosis. He was treated with rifampin, isoniazid, pyrazinamide, and ethambutol therapy, colchicine, and a steroid taper, resulting in clinical improvement. TBP is rare in developed regions and presents diagnostic challenges because of nonspecific symptoms and delayed culture results. Early recognition and intervention are critical to prevent progression to constrictive pericarditis and improve outcomes. A high index of suspicion for TBP is essential in patients with pericardial effusion to enable timely diagnosis and intervention, optimizing clinical outcomes.